| Publication |
Sentence |
Publish Date |
Extraction Date |
Species |
| João Carlos Locatelli, Juliene Gonçalves Costa, Andrew Haynes, Louise H Naylor, P Gerry Fegan, Bu B Yeap, Daniel J Gree. Incretin-Based Weight Loss Pharmacotherapy: Can Resistance Exercise Optimize Changes in Body Composition? Diabetes care. 2024-04-30. PMID:38687506. |
liraglutide and semaglutide (glp-1ra), tirzepatide (glp-1 and gip receptor dual agonist), and retatrutide (glp-1, gip, and glucagon receptor triple agonist) are peptides with incretin agonist activity that induce ∼15-24% weight loss in adults with overweight and obesity, alongside beneficial impacts on blood pressure, cholesterol, blood glucose, and insulin. |
2024-04-30 |
2024-05-03 |
Not clear |
| Giulia Angelini, Sara Russo, Geltrude Mingron. Incretin hormones, obesity and gut microbiota. Peptides. 2024-04-18. PMID:38636809. |
gip (glucose-dependent insulinotropic polypeptide) and glp-1 (glucagon-like peptide-1), which are secreted from the intestine after nutrient intake and stimulate insulin secretion from pancreatic β cells, influence lipid metabolism, gastric empting, appetite and body weight. |
2024-04-18 |
2024-04-21 |
Not clear |
| Anne-Sofie H Jensen, Henriette Ytting, Mikkel P Werge, Elias B Rashu, Liv E Hetland, Mira Thing, Puria Nabilou, Johan Burisch, Kirstine N Bojsen-Møller, Anders E Junker, Lise Hobolth, Christian Mortensen, Flemming Tofteng, Flemming Bendtsen, Søren Møller, Mogens Vyberg, Reza R Serizawa, Lise L Gluud, Nicolai J Wewer Albrechtse. Patients with autoimmune liver disease have glucose disturbances that mechanistically differ from steatotic liver disease. American journal of physiology. Gastrointestinal and liver physiology. 2024-04-16. PMID:38625142. |
we measured the concentrations of glucose, c-peptide, insulin, glucagon, the two incretin hormones glucose insulinotropic peptide (gip) and glucagon-like peptide-1 (glp-1). |
2024-04-16 |
2024-04-18 |
Not clear |
| Lampros G Chrysavgis, Spyridon Kazanas, Konstantina Bafa, Sophia Rozani, Maria-Evangelia Koloutsou, Evangelos Cholongita. Glucagon-like Peptide 1, Glucose-Dependent Insulinotropic Polypeptide, and Glucagon Receptor Agonists in Metabolic Dysfunction-Associated Steatotic Liver Disease: Novel Medication in New Liver Disease Nomenclature. International journal of molecular sciences. vol 25. issue 7. 2024-04-13. PMID:38612640. |
glucagon-like peptide 1 (glp-1) and glucose-dependent insulinotropic polypeptide (gip) are incretins that regulate postprandial glucose regulation, stimulating insulin secretion from pancreatic β-cells in response to food ingestion. |
2024-04-13 |
2024-04-15 |
human |
| Samrin Kagdi, Sulayman Lyons, Jacqueline L Beaudr. The interplay of glucose-dependent insulinotropic polypeptide in adipose tissue. The Journal of endocrinology. 2024-04-05. PMID:38579777. |
glucose-dependent insulinotropic polypeptide (gip) is an incretin hormone secreted from the small intestinal k-cells, responsible for augmenting insulin release, and has gained attention for its independent and amicable effects with glucagon-like peptide-1 (glp-1), another incretin hormone secreted from the small intestinal l-cells. |
2024-04-05 |
2024-04-10 |
human |
| Samrin Kagdi, Sulayman Lyons, Jacqueline L Beaudr. The interplay of glucose-dependent insulinotropic polypeptide in adipose tissue. The Journal of endocrinology. 2024-04-05. PMID:38579777. |
the gip receptor (gipr) is found in whole adipose tissue, whereas the glp-1 receptor (glp-1r) is not, and some studies suggest that gipr action lowers body weight and plays a role in lipolysis, glucose/lipid uptake/disposal, adipose tissue blood flow, lipid oxidation, and free-fatty acid (ffa) re-esterification that may or may not be influenced by other hormones such as insulin. |
2024-04-05 |
2024-04-10 |
human |
| Kayoko Kamemoto, Yusei Tataka, Ayano Hiratsu, Chihiro Nagayama, Yuka Hamada, Koji Kurata, Michiko Chiyoda, Machi Ito, Masashi Miyashit. Effect of vegetable consumption with chewing on postprandial glucose metabolism in healthy young men: a randomised controlled study. Scientific reports. vol 14. issue 1. 2024-03-30. PMID:38555375. |
circulating concentrations of glucose, insulin, total glucagon-like peptide-1 (glp-1) and glucose-dependent insulinotropic peptide (gip) concentrations were measured from the plasma. |
2024-03-30 |
2024-04-02 |
Not clear |
| Seun Akindehin, Arkadiusz Liskiewicz, Daniela Liskiewicz, Miriam Bernecker, Cristina Garcia-Caceres, Daniel J Drucker, Brian Finan, Gerald Grandl, Robert Gutgesell, Susanna M Hofmann, Ahmed Khalil, Xue Liu, Perla Cota, Mostafa Bakhti, Oliver Czarnecki, Aimée Bastidas-Ponce, Heiko Lickert, Lingru Kang, Gandhari Maity, Aaron Novikoff, Sebastian Parlee, Ekta Pathak, Sonja C Schriever, Michael Sterr, Siegfried Ussar, Qian Zhang, Richard DiMarchi, Matthias H Tschöp, Paul T Pfluger, Jonathan D Douros, Timo D Mülle. Loss of GIPR in LEPR cells impairs glucose control by GIP and GIP:GLP-1 co-agonism without affecting body weight and food intake in mice. Molecular metabolism. 2024-03-16. PMID:38492844. |
loss of gipr in lepr cells impairs glucose control by gip and gip:glp-1 co-agonism without affecting body weight and food intake in mice. |
2024-03-16 |
2024-03-19 |
mouse |
| Christopher Bannon, Claire Meek, Frank Reimann, Fiona M Gribbl. Fasting and Post Prandial Pancreatic and Enteroendocrine Hormone Levels in Obese and Non-Obese Participants. Peptides. 2024-03-15. PMID:38490484. |
participants: with healthy bmi (n=15), overweight bmi (n=29) and obesity (n=161) had samples taken fasting and 30min post mixed liquid meal for analysis of glucagon-like peptide-1 (glp-1), pyy, glucose-dependent insulinotropic polypeptide (gip), insulin and glucagon. |
2024-03-15 |
2024-03-18 |
human |
| Dorte B Zilstorff, Michael M Richter, Jens Hannibal, Henrik L Jørgensen, Henriette P Sennels, Nicolai J Wewer Albrechtse. Secretion of glucagon, GLP-1 and GIP may be affected by circadian rhythm in healthy males. BMC endocrine disorders. vol 24. issue 1. 2024-03-14. PMID:38481208. |
glucagon-like peptide-1 (glp-1) and glucose-dependent insulinotropic polypeptide (gip) are secreted from gut endocrine cells during meals and control glucose homeostasis by potentiating insulin secretion and inhibiting food intake. |
2024-03-14 |
2024-03-16 |
Not clear |
| Xin Jiang, Ji Li, Xiaohui Yao, Hao Ding, Aihong Gu, Zhen Zho. Neuroprotective effects of dipeptidyl peptidase 4 inhibitor on Alzheimer's disease: a narrative review. Frontiers in pharmacology. vol 15. 2024-02-26. PMID:38405664. |
beyond dpp4i's benefits in alleviating insulin resistance and glucose-lowering, underlying mechanisms for the potential neuroprotection with dpp4i medications were categorized into the following sections: (ferrari et al., physiol rev, 2021, 101, 1,047-1,081): the benefits of dpp4is on directly ameliorating the burden of β-amyloid plaques and reducing the formation of neurofibrillary tangles; dpp4i increasing the bioactivity of neuroprotective dpp4 substrates including glucagon-like peptide-1 (glp-1), glucose-dependent insulinotropic peptide (gip), and stromal-derived factor-1α (sdf-1α) etc. |
2024-02-26 |
2024-02-28 |
Not clear |
| Rolien Bosch, Marcella Petrone, Rosalin Arends, Paolo Vicini, Eric J G Sijbrands, Sven Hoefman, Nelleke Snelde. Characterisation of cotadutide's dual GLP-1/glucagon receptor agonistic effects on glycaemic control using an in vivo human glucose regulation quantitative systems pharmacology model. British journal of pharmacology. 2024-02-25. PMID:38403793. |
we characterised the effects of cotadutide on glucose, insulin, glp-1, gip, and glucagon over time in a quantitative manner using our glucose dynamics systems model (4gi systems model), in combination with clinical data from a multiple ascending dose/phase 2a (mad/ph2a) study in overweight and obese subjects with a history of type 2 diabetes mellitus (nct02548585). |
2024-02-25 |
2024-02-28 |
human |
| Snehasish Nag, Samanwita Mandal, Oindrila Mukherjee, Tanmay Majumdar, Satinath Mukhopadhyay, Rakesh Kund. Vildagliptin inhibits high fat and fetuin-A mediated DPP-4 expression, intracellular lipid accumulation and improves insulin secretory defects in pancreatic beta cells. Biochimica et biophysica acta. Molecular basis of disease. vol 1870. issue 3. 2024-02-03. PMID:38296116. |
dipeptidyl peptidase-4 (dpp-4), a ubiquitous proteolytic enzyme, inhibits insulin secretion from pancreatic beta cells by inactivating circulating incretin hormones glp-1 and gip. |
2024-02-03 |
2024-02-06 |
mouse |
| Eka Melson, Uzma Ashraf, Dimitris Papamargaritis, Melanie J Davie. What is the pipeline for future medications for obesity? International journal of obesity (2005). 2024-02-01. PMID:38302593. |
looking to the next generation of obesity treatments, combinations of glp-1 with other entero-pancreatic hormones with complementary actions and/or synergistic potential (such as glucose-dependent insulinotropic polypeptide (gip), glucagon, and amylin) are under investigation to enhance the wl and cardiometabolic benefits of glp-1 ra. |
2024-02-01 |
2024-02-04 |
Not clear |
| Marta Santos Hernandez, Frank Reimann, Fiona M Gribbl. Cellular mechanisms of incretin hormone secretion. Journal of molecular endocrinology. 2024-01-19. PMID:38240302. |
the incretin hormones glucagon-like peptide-1 (glp-1) and glucose-dependent insulinotropic polypeptide (gip) are involved in the regulation of insulin secretion, appetite, food intake and body weight after their nutrient-induced secretion from the gut. |
2024-01-19 |
2024-01-21 |
Not clear |
| Landon S Deru, Elizabeth Z Gipson, Katelynn E Hales, Benjamin T Bikman, Lance E Davidson, Benjamin D Horne, James D LeCheminant, Larry A Tucker, Bruce W Baile. The Effects of a High-Carbohydrate versus a High-Fat Shake on Biomarkers of Metabolism and Glycemic Control When Used to Interrupt a 38-h Fast: A Randomized Crossover Study. Nutrients. vol 16. issue 1. 2024-01-11. PMID:38201992. |
this study aimed to determine the impact of various fast-interrupting shakes on markers of glycemic control including glucose, β-hydroxybutyrate (bhb), insulin, glucagon, glp-1, and gip. |
2024-01-11 |
2024-01-13 |
Not clear |
| Vijaya Subramanian, Jonatan I Bagger, Vinayak Harihar, Jens J Holst, Filip K Knop, Tina Vilsbøl. An Extended Minimal Model of OGTT: Estimation of Alpha- and Beta-Cell Dysfunction, Insulin Resistance, and the Incretin Effect. American journal of physiology. Endocrinology and metabolism. 2023-12-13. PMID:38088864. |
the extended model describes glucose and hormone dynamics in ogtt including the contribution of the incretins, glucagon-like peptide-1 (glp-1) and glucose-dependent insulinotropic polypeptide (gip), to insulin secretion. |
2023-12-13 |
2023-12-17 |
human |
| Rikke Viggers, Nicklas Højgaard-Hessellund Rasmussen, Peter Vestergaar. Effects of Incretin Therapy on Skeletal Health in Type 2 Diabetes-A Systematic Review. JBMR plus. vol 7. issue 11. 2023-12-01. PMID:38025038. |
the group of hormones known as incretins, which includes gastric inhibitory peptide (gip) and glucagon-like peptide 1 (glp-1), play a role in regulating bowel function and insulin secretion during feeding. |
2023-12-01 |
2023-12-07 |
human |
| Rikke Viggers, Nicklas Højgaard-Hessellund Rasmussen, Peter Vestergaar. Effects of Incretin Therapy on Skeletal Health in Type 2 Diabetes-A Systematic Review. JBMR plus. vol 7. issue 11. 2023-12-01. PMID:38025038. |
the group of hormones known as incretins, which includes gastric inhibitory peptide (gip) and glucagon-like peptide 1 (glp-1), play a role in regulating bowel function and insulin secretion during feeding. |
2023-11-29 |
2023-12-07 |
human |
| Julia Herrou, Guillaume Mabilleau, Jean-Michel Lecerf, Thierry Thomas, Emmanuel Biver, Julien Pacco. Narrative Review of Effects of Glucagon-Like Peptide-1 Receptor Agonists on Bone Health in People Living with Obesity. Calcified tissue international. 2023-11-24. PMID:37999750. |
further studies are needed to investigate the bone impact of glp-1ra, dual- and triple-receptor agonists for glp-1, glucose-dependent insulin releasing polypeptide (gip), and glucagon in pwo. |
2023-11-24 |
2023-11-29 |
Not clear |